http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08176011-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f8af7906235bed6c1199b28234b5f85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23 |
| filingDate | 1994-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24167fff635a6eda7b70526d96cc0ad6 |
| publicationDate | 1996-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08176011-A |
| titleOfInvention | Aseptic osteonecrosis syndrome therapeutic agent |
| abstract | (57) [Summary] [Objective] To provide a therapeutic agent for aseptic osteonecrosis syndrome such as aseptic necrosis and non-rotless necrosis, which are intractable diseases. A composition for treating aseptic osteonecrosis syndrome, which comprises calcitonin as an active ingredient. Further, a therapeutic agent for aseptic osteonecrosis syndrome, wherein an effective amount of calcitonin is uniformly dispersed and adhered to hydroxyapatite or magnesium stearate which is a physiologically acceptable polyvalent metal carrier having an average particle size of 250 μm or less. I will provide a. Such therapeutic agents are in the form of nasal formulations. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007035455-A3 |
| priorityDate | 1994-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.